Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
AstraZeneca
Dow
Colorcon
McKinsey

Last Updated: January 26, 2023

Investigational Drug Information for AZD9977


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for AZD9977?

AZD9977 is an investigational drug.

There have been 13 clinical trials for AZD9977. The most recent clinical trial was a Phase 1 trial, which was initiated on January 26th 2021.

The most common disease conditions in clinical trials are Heart Failure, Cardiovascular Diseases, and Renal Insufficiency, Chronic. The leading clinical trial sponsors are AstraZeneca, Parexel, and Quotient Sciences.

There are three US patents protecting this investigational drug and fifty-one international patents.

Recent Clinical Trials for AZD9977
TitleSponsorPhase
Study to Assess the Bioavailability of Different Formulations of AZD9977 and Dapagliflozin and Influence of Food in Selected Formulations in Healthy VolunteersParexelPhase 1
Study to Assess the Bioavailability of Different Formulations of AZD9977 and Dapagliflozin and Influence of Food in Selected Formulations in Healthy VolunteersAstraZenecaPhase 1
Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney DiseaseAstraZenecaPhase 2

See all AZD9977 clinical trials

Clinical Trial Summary for AZD9977

Top disease conditions for AZD9977
Top clinical trial sponsors for AZD9977

See all AZD9977 clinical trials

US Patents for AZD9977

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD9977 See Plans and Pricing Benzoxazinone amides as mineralocorticoid receptor modulators AstraZeneca AB (Sodertalje, SE) See Plans and Pricing
AZD9977 See Plans and Pricing Methods of treating heart failure with reduced ejection fraction ASTRAZENECA AB (Sodertalje, SE) See Plans and Pricing
AZD9977 See Plans and Pricing Benzoxazinone amides as mineralocorticoid receptor modulators AstraZeneca AB (Sodertalje, SE) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD9977

Drugname Country Document Number Estimated Expiration Related US Patent
AZD9977 Argentina AR101036 2034-06-30 See Plans and Pricing
AZD9977 Australia AU2015282450 2034-06-30 See Plans and Pricing
AZD9977 Canada CA2953655 2034-06-30 See Plans and Pricing
AZD9977 China CN106536491 2034-06-30 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
AstraZeneca
Dow
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.